Inside Moderna’s Biggest mRNA Test Since COVID

a16z · 2026-09-02 · 39 分鐘
https://www.youtube.com/watch?v=yTNMEYeCgWw影片總結
Moderna and Merck report positive Phase 3 melanoma results for an individualized mRNA vaccine added to Keytruda after a decade of development.
Moderna CEO Stéphane Bancel tells a16z’s Jorge Conde that Moderna and Merck’s personalized mRNA cancer treatment met its Phase 3 primary endpoint of recurrence-free survival in melanoma, and also its secondary endpoint of distant metastasis-free survival. In an earlier Phase 2 study, about 80% of patients were disease-free five years after treatment; Bancel hopes to file with regulators and make the treatment available as early as 2027. The vaccine compares tumor and healthy-cell DNA, then uses an algorithm to select up to 34 mutations and encode them in a patient-specific mRNA dose. Bancel says doses take about 42 days to produce, with a Massachusetts facility able to make tens of thousands annually. Moderna plans trials across other cancers, including lung, kidney, bladder, pancreatic and gastric cancers, while using Phase 3 patient data to improve its algorithm. He also describes future mRNA work in rare genetic liver diseases and autoimmune disease.
章節
- 0:00How Moderna Went From COVID to Cancer: Personalized Tumor Sequencing and Phase 3 Melanoma News
- 2:48The Phase 3 News: Moderna and Merck’s Melanoma Vaccine Meets Two Survival Endpoints
- 5:46What Is Keytruda & Why Isn't It Enough Alone? Keytruda’s 60% Five-Year Result and Targeted T Cells
- 9:23Preventing the Return of Cancer: The Vaccine Retrains Immunity to Recognize Missed Cancer Signals
- 11:16Why 20 Years and 1,000 Trials Failed Before mRNA Worked: 34 Personalized Mutations and 90% Different Antigens
- 15:09Inside the Algorithm: Moderna’s 10-Year-Old Neoantigen Model and Plans for Version 2.0
- 18:48The Operational Lift of Making a Vaccine for Every Patient: Tailored Doses Versus CAR T Cell Engineering
- 20:16Vein to Vein: Moderna’s 42-Day Personalized Vaccine Process and Factory-Efficiency Push
- 24:33Manufacturing at Scale & the COGS Question: Marlborough Capacity and Undisclosed Pricing
- 27:08How Do You Regulate a Medicine That's Different Every Time? Process BLA and Consistent Manufacturing
- 29:37Beyond Melanoma: Moderna Targets Lung, Kidney, Bladder, Pancreatic, and Gastric Cancers
- 35:58From COVID to Cancer to Autoimmune Disease: Moderna Advances Rare Liver and Personalized Treatments
完整分析還有什麼
12 章 · 57 個重點 · 12 段段落總結 · 心智圖
第一章預覽 · How Moderna Went From COVID to Cancer: Personalized Tumor Sequencing and Phase 3 Melanoma News
其餘 54 個重點、段落總結與心智圖在完整分析裡。 分析這支影片,看完整內容 →
這支影片 39 分鐘,免費方案可分析 30 分鐘以內的影片;Plus 方案起可分析 2 小時以內。
這是 Tier 1 公開摘要
每章重點、段落總結、心智圖由分享者控制是否公開。想看完整分析?自己提交一支。
同頻道的其他分析
Why AI Could Turn Small Law Firms Into Billion-Dollar Businessesa16zEve CEO Jay Madheswaran says AI helped an LA law firm grow from 100 to 500 clients per attorney by automating plaintiff-law work.
Why Founders Are Betting Big on Factories, Mines, and Energya16za16z investors argue defense demand can rebuild U.S. factories, mines, and energy while creating commercial markets for robotics.
Mark Cuban on Why AI Could Turn Solo Founders Into Trillionairesa16zMark Cuban says AI could expose healthcare contract abuses, while Cost Plus Drugs bets $20 million manufacturing pods can lower drug costs.
The AI School Kids Love More Than Vacation | Alpha School's Joe Liemandta16zAlpha School’s Joe Liemandt says students master academics in two hours and learn teamwork by reaching 85% team behavior.
What Today’s Best Models Still Can’t Do in Matha16zDaniel Litt praises AI’s Erdős unit-distance result but warns that proof generation is not the same as mathematical understanding.

